MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2016 International Congress

    Multi-parameter imaging in hemidystonia responsive to GPi deep brain stimulation

    C. Sidiropoulos, S. Bowyer, A. Zillgitt, P.A. LeWitt, H. Bagher-Ebadian, E. Davoodi-Bojd, J.M. Schwalb, H. Soltanian-Zadeh (West Bloomfield, MI, USA)

    Objective: To present i) imaging data in a case of hemidystonia using structural (diffusion tensor imaging-DTI and fiber tractography-FT) and functional (functional MRI-fMRI and magnetoencephalography-MEG)…
  • 2016 International Congress

    The anatomical basis of genetic dystonia: A multimodal MRI study

    E. Sarasso, F. Agosta, A. Tomic, S. Basaia, N. Dragasevic, M. Svetel, M. Copetti, V.S. Kostic, M. Filippi (Milan, Italy)

    Objective: We aimed at investigating structural and functional alterations in asymptomatic (aDYT) and symptomatic dystonia (sDYT) mutation carriers. Background: Most of DYT genotypes follow an…
  • 2016 International Congress

    Structural and connectivity changes after botulinum neurotoxin therapy in blepharospasmus and hemifacial spasm

    C.V. Chirumamilla, G. Deuschl, K.E. Zeuner, M. Muthuraman, S. Groppa (Mainz, Germany)

    Objective: The two primary objectives of this study were to investigate the structural grey matter changes and connectivity differences between patients with BEB and HFS…
  • 2016 International Congress

    Heterozygous TUBB4A knock-out impairs mitochondrial motility in human neuronal model of DYT4

    V. Krajka, F. Vulinovic, P. Seibler, K. Lohmann, C. Klein, A. Rakovic (Luebeck, Germany)

    Objective: To study the role of tubulin beta 4A (TUBB4A) in mitochondrial motility in isogenic induced pluripotent stem cells (iPSC)-derived neurons. Background: Heterozygous mutations in…
  • 2016 International Congress

    Are we speaking the same language? A pilot study to evaluate the agreement in clinical phenotyping of children with cerebral palsy

    H. Eggink, D. Kremer, O.F. Brouwer, M.F. Contarino, M.E. van Egmond, A. Elema, K. Folmer, J.F. van Hoorn, L.A. van de Pol, V. Roelfsema, M.A.J. Tijssen (Groningen, Netherlands)

    Objective: The aim of this pilot study was determine the agreement of phenotypical classification of children with cerebral palsy among clinicians. Background: Cerebral palsy (CP)…
  • 2016 International Congress

    Nursing diagnoses and interventions in rehabilitation related to antiParkinsonian pharmacotherapy

    M.H.S. Tosin, B.G.R.B. Oliveira, T.R. Garcia (Rio de Janeiro, Brazil)

    Objective: To analyze the role of nurses in antiParkinsonian pharmacotherapy based on the International Classification for Nursing Practice (ICNP®). Background: Although it is considered an…
  • 2016 International Congress

    The effect of daytime working for development of sleep apnea in office workers

    D.M. Sultonov, U.N. Vokhidov (Tashkent, Uzbekistan)

    Objective: Nowadays sleep apnea becomes the one of the most general problem in each sphere. Every day, the role of sleep apnea in the development…
  • 2016 International Congress

    Effectiveness of Lee Silverman voice treatment big on improving gait and quality of life in Parkinson’s disease patients after STN-DBS

    V.V.P. Kagita, N.N. Mohd, A.K. Puligopu, R.M. Kandadai, M.A. Kanikannan, S. Jabeen, R. Borgohain (Hyderabad, India)

    Objective: To study effectiveness of Intensive amplitude specific exercise training of LSVT [Lee Silverman Voice Treatment] BIG on improving gait and quality of life in…
  • 2016 International Congress

    Development of a nanoherbaceutical containing natural L-DOPA from mucuna pruriens for the prevention and treatment of Parkinson’s disease in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced animal model

    P.C. Bhatt, V. Kumar (New Delhi, India)

    Objective: To prepare and evaluate the nanoherbaceutical formulation containing natural L-DOPA from Mucuna pruriens against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced Parkinson's disease (PD). Background: PD is…
  • 2016 International Congress

    Successful treatment of movement disorders after resection of midbrain cavernous malformations: Report of two cases

    A. Smolanka, V. Smolanka, K. Karpinska, M. Dovhanych, T. Havryliv (Uzhhorod, Ukraine)

    Objective: To evaluate the treatment of movement disorders which presented as a consequence of haemorrhage from midbrain cavernous malformations. Background: Few cases of movement disorders…
  • « Previous Page
  • 1
  • …
  • 11
  • 12
  • 13
  • 14
  • 15
  • …
  • 207
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • An atypical and interesting feature of Parkinson´s disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • #23812 (not found)
  • Approaching Health Care Shaped by Generational Expectations (The AGE Study): Generational Perspective Related to Time
  • Application of the “5-2-1” Screening Criteria in Advanced Parkinson’s Disease Patients Treated with Levodopa-Carbidopa Intestinal Gel: Interim Analysis from the DUOGLOBE Study
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
  • An atypical and interesting feature of Parkinson´s disease
  • Patients with Essential Tremor Live Longer than their Relatives
  • DaTscan in clinical evaluation of Multiple System Atrophy
  • Decision-making process for opicapone’s bedtime regimen
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley